Worthy Christian News > Israel-Palestinian Conflict > Israel to offer breakthrough cancer treatment through genomic profiling

Israel to offer breakthrough cancer treatment through genomic profiling

by Karen Faulkner, Worthy News Correspondent

(Worthy News) – In a breakthrough for cancer care, Israel’s Hadassah-University Medical Center in Jerusalem is officially partnering with the Roche-Israel pharmaceutical company to promote personalized oncology treatment based on the patient’s genomic profile, the Jerusalem Post reports. Genomic profiling identifies DNA mutations within a cancerous tumor to determine how it behaves and grows.

The partnership will be Israel’s first such integrated model agreement and will allow Hadassah to offer profiling tests based on molecular and bioinformatics that will enable precise disease-targeted treatment at every stage, JPost reports. The AVENIO kit will be used for solid tumor diagnostics, and Foundation Medicine tests will be conducted and sent to labs abroad for analysis.

“Implementing the integrated model will allow us to provide patients with the most advanced and innovative diagnostic tests for cancer,” Hadassah Medical Organization director-general Prof. Yoram Weiss said in a statement.

“This collaboration is the result of concerted work by our teams to establish a unique model that positions Hadassah at the forefront of personalized cancer care in Israel and worldwide,” Weiss continued. “Genomic testing for each patient will allow us to understand the molecular characteristics of the tumor and provide the most precise treatment available, among the treatments available in Israel and within the clinical trial framework, leading to the best possible outcomes. It will also make it possible for us to develop more AI-based tools to enhance patient care.”

Netanel Amichai, director-general of Roche Diagnostics Israel, and Avi Danziger, head of Roche Pharmaceuticals Israel, added in a separate statement: “In addition to clinical advantages, this partnership will significantly advance scientific and research aspects of cancer management, potentially leading to further collaborative efforts that stem from this important milestone.”